Compounds and compositions as protein kinase inhibitors

A method for treating a B-Raf protein kinase mediated cancer, wherein the cancer is selected from the group consisting of lung carcinoma, pancreatic carcinoma, bladder carcinoma, colon carcinoma, myeloid disorders, prostate cancer, thyroid cancer, melanoma, adenomas and carcinomas of the ovary, eye, liver, biliary tract, and nervous system, and wherein the method comprises administering to a subject in need of such treatment an effective amount of a compound of Formula (Ia), or a tautomer, stereoisomer or pharmaceutically acceptable salt thereof;

• wherein the compound of Formula (Ia) is
• in which:
• Y is selected from N and CR6;
• R2, R3, R5 and R6 are independently selected from hydrogen, halo, cyano, C1-4alkyl, halo-substituted-C1-4alkyl, C1-4alkoxy and halo-substituted-C1-4alkoxy;
• with the proviso that when R5 is fluoro, R3 and R6 are not both hydrogen;
• R4 is selected from —R9 and —NR10R11;
• wherein R9 is selected from C1-6alkyl, C3-8cycloalkyl, C3-8heterocycloalkyl, aryl and heteroaryl;
• wherein
• said alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl of R9 is optionally substituted with 1 to 3 radicals independently selected from halo, cyano, C1-4alkyl, halo-substituted-C1-4alkyl, C1-4alkoxy and halo-substituted-C1-4alkoxy;
• and R10 and R11 are independently selected from hydrogen and R9;
• R7 is selected from hydrogen, C1-4alkyl, C3-5cycloalkyl and C3-5heterocycloalkyl;
• wherein said alkyl, cycloalkyl or heterocycloalkyl of R7 is optionally substituted with 1 to 3 radicals independently selected from halo, cyano, hydroxyl, C1-4alkyl, halo-substituted-C1-4alkyl, C1-4alkoxy and halo-substituted-C1-4alkoxy.